LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,997 | -13.2% | 64,404 | +3.7% | 0.00% | -100.0% |
| Q2 2023 | $87,581 | -8.8% | 62,114 | -0.2% | 0.00% | 0.0% |
| Q1 2022 | $96,000 | -41.1% | 62,265 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $163,000 | -5.8% | 66,647 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $173,000 | -10.8% | 68,642 | +1.0% | 0.00% | 0.0% |
| Q2 2021 | $194,000 | +266.0% | 67,948 | +6.1% | 0.00% | – |
| Q1 2020 | $53,000 | -11.7% | 64,022 | -5.5% | 0.00% | – |
| Q4 2019 | $60,000 | -10.4% | 67,720 | -0.8% | 0.00% | – |
| Q3 2019 | $67,000 | – | 68,290 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $83,313,000 | 5.12% |
| Defender Capital, LLC. | 4,997,870 | $12,245,000 | 3.92% |
| Raffles Associates | 543,590 | $1,332,000 | 1.28% |
| Prescott General Partners LLC | 1,851,851 | $4,537,000 | 0.16% |
| DCF Advisers, LLC | 85,000 | $208,000 | 0.08% |
| Long Focus Capital Management, LLC | 215,000 | $527,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $110,000 | 0.06% |
| DAFNA Capital Management LLC | 80,000 | $196,000 | 0.05% |
| Strategic Wealth Investment Group, LLC | 65,069 | $159,000 | 0.04% |
| Fort Sheridan Advisors LLC | 52,931 | $130,000 | 0.04% |